Actuate Therapeutics Announces Publication of Positive Phase II Clinical Data for Elraglusib Combined with Platinum Chemotherapy and Sequential Immunotherapy in Recurrent ...

Promising data show a median overall survival of 18.6 months, with 40% of patients alive at 2 years.Results suggest that nuclear GSK-3β ...
The Manila Times

Actuate Therapeutics Announces Publication of Positive Phase II Clinical Data for Elraglusib Combined with Platinum Chemotherapy and Sequential Immunotherapy i…

The combination was well tolerated: no treatment-related deaths occurred, and only 6% (2 patients) were discontinued due to ...
Healio

Beneath the Surface: Who should prescribe GLP-1s?

Use of GLP-1 receptor agonists, which have shown to be effective in diabetes and obesity treatment, is expanding into other ...

JAMA (Journal of the American Medical Association) Recognizes GUARDIAN Newborn Genomic Screening Study Among Its Research of the Year

The GUARDIAN study has been recognized as one of the most impactful scientific contributions published across all JAMA journals this year.